1 user’s guide Cary: SAS Institute Inc; 2012 29 Herland K, Aks

1 user’s guide. Cary: SAS Institute Inc; 2012. 29. Herland K, Akselsen JP, Skjonsberg OH, Bjermer L. How representative are clinical study patients with asthma or COPD for a larger “real life” population of patients with

obstructive lung disease? Respir Med. 2005;99(1):11–9.PubMedCrossRef 30. Travers J, Marsh S, Williams M, Weatherall M, Caldwell B, Shirtcliffe P, et al. External validity of randomized YAP-TEAD Inhibitor 1 controlled trials in asthma: to whom do the results of the trials apply? Thorax. 2007;62(3):219–23.PubMedCrossRef 31. Virchow JC, Crompton GK, Dal Negro R, Pedersen S, Magnan A, Seidenberg J, et al. Importance VX-689 of inhaler devices in the management of airway disease. Respir Med. 2008;102(1):10–9.PubMedCrossRef 32. Price D, Thomas M, Mitchell G, Niziol AZD0530 C, Featherstone R. Improvement of asthma control with a breath-actuated pressurised metered dose inhaler (BAI): a prescribing claims study of 5556 patients using a traditional pressurised metered dose inhaler (MDI) or a breath-actuated device. Respir Med. 2003;97(1):12–9.PubMedCrossRef 33. Price D, Haughney J, Sims E, Ali M, von Ziegenweidt J, Hillyer EV, et al. Effectiveness of inhaler types for real-world asthma management: retrospective observational study using the GPRD. J Asthma Allergy. 2011;4(1):37–47.PubMed 34. Crompton GK. Problems patients have using pressurized aerosol inhalers. Eur J Respir Dis. 1982;63(Suppl

119):101–9. 35. Hilton S. An audit of inhaler technique among asthma patients of 34 general practitioners. Br J Gen Pract. 1990;40(341):505–6.PubMed 36. Borgström L, Asking L, Thorsson L. Idealhalers or realhalers? A comparison of Diskus and Turbuhaler. Int J Clin Pract. 2005;59(12):1488–95.PubMedCrossRef 37. Borgström L, Derom E, Ståhl (-)-p-Bromotetramisole Oxalate E, Wåhlin-Boll E, Pauwels R. The inhalation device influences lung deposition and bronchodilating effect of terbutaline. Am J Respir Crit Care Med. 1996;153(5):1636–40.PubMedCrossRef 38. Borgström L, Bengtsson T, Derom E, Pauwels R. Variability in lung deposition of inhaled drug, within and between asthmatic

patients, with a pMDI and a dry powder inhaler, Turbuhaler. J Int Pharm. 2000;193(2):227–30.CrossRef 39. Borgström L. The importance of the device in asthma therapy. Respir Med. 2001;95(Suppl B):S26–9.PubMedCrossRef 40. Holgate S, Bisgaard H, Bjermer L, Haahtela T, Haughney J, Horne R, et al. The Brussels Declaration: the need for change in asthma management. Eur Respir J. 2008;32(6):1433–42.PubMedCrossRef”
“1 Introduction Lignocaine in high concentrations has the ability to block sodium channels and is used for local and regional anaesthesia and for antiarrhythmic treatment. Lignocaine is also thought to stabilize the cell membrane and have effects on inflammatory cells in lower concentrations [1, 2]. The definition of endometriosis is the presence of viable endometrial tissue outside the uterine cavity, most commonly located on the peritoneal surfaces in the lower abdominal cavity.

Comments are closed.